Download PDF
Thromb Haemost 1992; 67(01): 019-027
DOI: 10.1055/s-0038-1648373
Original Articles
Schattauer GmbH Stuttgart

Treatment of Hemophilia A with a Highly Purified Factor VIII Concentrate Prepared by Anti-FVIIIc Immunoaffinity Chromatography

Joseph E Addiego Jr.
The Children’s Hospital Medical Center of Northern California; Children’s Hospital Los Angeles; Baxter Healthcare Corporation, Hyland Division, Glendale, CA, USA
,
Edward Gomperts
The Children’s Hospital Medical Center of Northern California; Children’s Hospital Los Angeles; Baxter Healthcare Corporation, Hyland Division, Glendale, CA, USA
,
Liu Shu-Len
The Children’s Hospital Medical Center of Northern California; Children’s Hospital Los Angeles; Baxter Healthcare Corporation, Hyland Division, Glendale, CA, USA
,
Patricia Bailey
The Children’s Hospital Medical Center of Northern California; Children’s Hospital Los Angeles; Baxter Healthcare Corporation, Hyland Division, Glendale, CA, USA
,
Suzanne G Courter
The Children’s Hospital Medical Center of Northern California; Children’s Hospital Los Angeles; Baxter Healthcare Corporation, Hyland Division, Glendale, CA, USA
,
Martin L Lee
The Children’s Hospital Medical Center of Northern California; Children’s Hospital Los Angeles; Baxter Healthcare Corporation, Hyland Division, Glendale, CA, USA
,
Gerald G Neslund
The Children’s Hospital Medical Center of Northern California; Children’s Hospital Los Angeles; Baxter Healthcare Corporation, Hyland Division, Glendale, CA, USA
,
Henry S Kingdon
The Children’s Hospital Medical Center of Northern California; Children’s Hospital Los Angeles; Baxter Healthcare Corporation, Hyland Division, Glendale, CA, USA
,
Michael J Griffith
The Children’s Hospital Medical Center of Northern California; Children’s Hospital Los Angeles; Baxter Healthcare Corporation, Hyland Division, Glendale, CA, USA
› Author Affiliations
Further Information

Publication History

Received 29 December 1990

Accepted after revision 26 July 1991

Publication Date:
02 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

To reduce the risk of pathogenic virus transmission associated with the therapeutic administration of plasma-derived antihemophilic factor (FVIIIc), a process utilizing anti-FVIIIc immunoaffinity chromatography to isolate FVIIIc has been developed. In addition, the starting cryoprecipitate solution has been treated with an organic solvent/detergent mixture to inactivate lipid-enveloped viruses. A final ion exchange chromatography step is used to further remove contaminants, e.g., anti-FVIIIc antibody, potentially leached with FVIIIc during the immunoaffinity step. The purified FVTII is stabilized for lyophili-zation and storage by the addition of human albumin. The monoclonal anti-FVIIIc antibody used in the immunoaffinity step of the process is not detectable in the final preparation. Viral reduction studies performed at specific steps of the process demonstrate that 11 logs of human immunodeficiency virus (HIV) and greater than 4-5 logs of other lipid-enveloped viruses are inactivated within the first 30 s of exposure to the solvent/ detergent mixture and 4-5 logs of various model viruses, e. g. Endomyocarditis virus (EMC), are physically removed during washing of the immunoaffinity column. The lyophilized product is reconstituted using sterile water in a matter of seconds.

The pharmacokinetics of Hemofil® M were compared to those obtained using a standard heat-treated concentrate (Hemofil® CT) in five severe factor VIII deficient hemophiliacs in a randomized, cross-over study. No statistically significant differences were observed in mean half life (p >0.6) or median recovery (p = 0.4) between the two preparations. No clinically significant adverse effects were observed in patients receiving either FVIII preparation.

In addition, 43 patients at 18 different centers underwent pharmacokinetic studies, with a nominal dose of 50 u/kg FVIIIc Hemofil® M. The mean recovery was 103.6%, and the t 1/2 was 14.6 h. The recovery of FVIII in this group was as expected, providing an increase of assayed FVIII of approximately 2% per unit of FVTII/kg infused.

Clinical trials using Hemofil® M have been initiated in 124 hemophilia A patients. The safety and efficacy of Hemofil® M has been established. To date, 0 of 60 patients tested have seroconverted to HIV. None of the previously untreated patients show clinical or laboratory evidence of Non-A, Non-B hepatitis (NANB), with 21 patients remaining negative as far as presence of antibodies to the Hepatitis C virus (a-HCV negative) at least 6 months after the initial infusion. There is no evidence of neoantigenicity, evidenced by seroconversion to murine antibody. An 8.7% (2 of 23) prevalence of anti-FVIIIc inhibitor development has been observed in previously untreated patients with FVIIIc⩽3%, receiving only the monoclonally purified solvent/ detergent treated FVIII concentrate while on study and on poststudy surveillance. All patients demonstrated clinical hemostasis following product use for either on demand bleeding or surgical prophylaxis.

 

  • References

  • 1 Colombo M, Carnelli V, Gazengel C, Mannucci PM, Savidge GF, Schimpf K. and the European Study Group Transmission of non-A, non-B hepatitis by heat-treated factor VIII concentrate. Lancet 1985; 2: 1
    PubMedGoogle Scholar
  • 2 Fletcher ML, Trowell JM, Craske J, Pavier K, Rizza CR. Non-A, non-B hepatitis after transfusion of factor VIII in infrequently treated patients. Br Med J 1983; 287: 1754
    CrossrefPubMedGoogle Scholar
  • 3 Hay CRM, Tuger DR, Preston FE, Underwood JCE. Progressive liver disease in haemophilia. Lancet 1985; 1: 1495
    PubMedGoogle Scholar
  • 4 Kernoff PBA, Lee CA, Karayiannis P, Thomas HC. High risk of nonA, non-B hepatitis after a first exposure to volunteer or commercial clotting factor concentrates: effects of pooled human immunoglobulin. Br J Haematol 1984; 58: 174
    PubMedGoogle Scholar
  • 5 Ludlam CA, Peutherer JF. Hepatitis B infection in haemophilia. Lancet 1982; 2: 776
    PubMedGoogle Scholar
  • 6 Norkrans G, Widell A, Teger-Nilsson A-C, Kjellman H, Frosner G, Iwarson S. Acute hepatitis non-A, non-B following administration of factor VIII concentrates. Vox Sang 1981; 41: 129
    CrossrefPubMedGoogle Scholar
  • 7 Yap P. Hepatitis transmission by blood products. J Hosp Inf 1988; 11 (Suppl A) 166
    CrossrefPubMedGoogle Scholar
  • 8 Centers for Disease Control. Update: acquired immunodeficiency syndrome (AIDS) in persons with hemophilia. Mortality Morbidity Weekly Rep. 1984 33. 589
    PubMedGoogle Scholar
  • 9 Centers for Disease Control. Changing patterns of acquired immunodeficiency syndrome in hemophilia patients. Mortality Morbidity Weekly Rep. 1985 34. 241
    PubMedGoogle Scholar
  • 10 Daenen S, Hoogeveen Y, Smith JW, van Imhoff GW, van der Meer J, de Wolf JTM, Smit CTH. et al Risk of transmission of HIV by heat treated factor VIII concentrates in patients with severe hemophilia A. Transfusion 1987; 27: 482
    CrossrefPubMedGoogle Scholar
  • 11 Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256: 497
    PubMedGoogle Scholar
  • 12 March SC, Parikk I, Cuatrecasas R. A simplified method for cyanogen bromide activation of agarose for affinity chromatography. Ann Biochem 1974; 60: 149
    CrossrefPubMedGoogle Scholar
  • 13 Laemmli ULK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680
    CrossrefPubMedGoogle Scholar
  • 14 Towbin H, Staehelin T, Gordon H. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: Procedure and some application. Proc Natl Acad Sci USA 1979; 76: 4350
    CrossrefPubMedGoogle Scholar
  • 15 Langdell RD, Wagner RH, Brinkhous KM. Effect of antihemophilic factor on one-stage clotting test. J Lab Clin Med 1953; 41: 637
    PubMedGoogle Scholar
  • 16 Reisner HM, Barrow ES, Graham JB. Radioimmunoassay for coagulant FVIII related antigen (VIII: Ag). Thromb Res 1979; 14: 235
    CrossrefPubMedGoogle Scholar
  • 17 Bartlett A, Bidwell DE, Voller A. Practical methods for the detection of antigens by ELISA. Protides Biol Fluids Proc Colloq 1976; 24: 767
    PubMedGoogle Scholar
  • 18 Piszkiewicz D, Kingdon H, Apfelzweig R, McDougal JS, Cort S, Andrews J, Hope H, Cabridilla CD. Inactivation of HTLV-III/LAV during plasma fractionation. Lancet 1985; 2: 1188
    PubMedGoogle Scholar
  • 19 Feorino P, Forrester B, Schable C, Warfield D, Schochetman G. Comparison of antigen assay and reverse transcriptase assay for detecting human immunodeficiency in culture. J Clin Micro 1987; 25: 2344
    PubMedGoogle Scholar
  • 20 Lee ML, Poon W, Kingdon HSA. Two-phase linear regression model for biologic half life data. J Lab Clin Med 1990; 115: 745
    PubMedGoogle Scholar
  • 21 Ingerslev J, Wallevik K. Quantities of Murine Immunoglobulin and Factor VIII:Ag in FVIII Concentrates Prepared by Monoclonal Antibody Techniques. Proceedings of the Symposium on Recent Advances in Hemophilia Care, Los Angeles, April 13-15, 1989. A. R. Liss; New York: 1990. p 325
    Google Scholar
  • 22 Fulcher CA, Zimmerman TS. Characterization of the human procoagulant factor VIII protein with a heterologous precipitating antibody. Proc Natl Acad Sci USA 1982; 79: 1648
    CrossrefPubMedGoogle Scholar
  • 23 Fulcher CA, Roberts JR, Holland LA, Zimmerman TS. Human factor VIII procoagulant protein. Monoclonal antibodies define precursor-product relationships and functional epitopes. J Clin Invest 1985; 76: 117
    CrossrefPubMedGoogle Scholar
  • 24 Rotblat F, O’Brien DP, O’Brien FJ, Goodall AH, Tuddenham EGD. Purification of human factor VIII :C and its characterization by western blotting using monoclonal antibodies. Biochemistry 1985; 24: 4294
    CrossrefPubMedGoogle Scholar
  • 25 Andersson L-O, Forsman N, Huang K, Larsen K, Lundin A, Pavlu B, Sandberg H, Sewerin K, Smart J. Isolation and characterization of human factor VIII: Molecular forms in commercial factor VIII concentrate, cryoprecipitate, and plasma. Proc Natl Acad Sci USA 1986; 85: 2979
    PubMedGoogle Scholar
  • 26 Eaton DL, Rodriguez HR, Vehar GA. Proteolytic processing of human factor VIII. Correlation of specific cleavages by thrombin, factor Xa, and activated protein C with activation and inactivation of factor VIII coagulant activity. Biochemistry 1986; 25: 505
    CrossrefPubMedGoogle Scholar
  • 27 Conover WJ. Practical Nonparametric Statistical Analysis. 4th edition. McGraw-Hill Book Co.; New York: 1980. pp 280
  • 28 Dixon WT, Massey FJ. Introduction of Statistical Analysis. 4th edition. McGraw-Hill Book Co.; New York: 1983. pp 127
  • 29 Lee ML, Kingdon HS. Methods for the analysis of factor VIII half-life data. Thromb Haemostas 1983; 50 (01) 244
    PubMedGoogle Scholar
  • 30 International Committee on Thrombosis and Hemostasis. ICTH critera for the prospective hepatitis virus safety studies of recipients of factor concentrates. In: AIDS Update: Medical Bulletin 69. National Hemophilia Foundation; New York: 1988: 1
    Google Scholar
  • 31 Heptavax-B®. Direction Insert. Merck, Sharp and Dohme, West Point, PA.
    PubMed
  • 32 Brettler DB, Levine PH. Factor concentrates for treatment of hemophilia: which one to choose?. Blood 1989; 73: 2067
    PubMedGoogle Scholar
  • 33 Ehrenkranz NJ, Rubini J, Gunn R, Horsburgh CR, Collins T, Hasiba U, Hathaway W, Doig W, Hopkins R, Elliott J, Hoppes W, Krill CE, Halpin T. Pneumocystis carinii pneumonia among patients with hemophilia A. Mortality Morbidity Weekly Rep 1982; 31: 365
    PubMedGoogle Scholar
  • 34 Evatt BL, Francis DP, McLane MF. et al Antibodies to human T cell leukemia virus associated membrane antigen in hemophiliacs: evidence for infection before 1980. Lancet 1983; 1: 698
    PubMedGoogle Scholar
  • 35 Gomperts E, Jordan S, Berg D, Sakai R, Boylin L. Circulating immune complexes pre and post clotting factor infusion in hemophiliacs. Thromb Haemostas 1981; 46: 694-698
    PubMedGoogle Scholar
  • 36 Lederman MM, Ratnoff OD, Evatt BL, McDougal JS. Acquisition of antibody to lymphadenopathy-associated virus in patients with classic hemophilia (factor VIII deficiency). Ann Intern Med 1985; 102: 753
    CrossrefPubMedGoogle Scholar
  • 37 Lederman MM, Saunders C, Toosii Z, Lemon N, Everson B, Ratnoff OD. Antihemophilic factor (factor VIII) preparations inhibit lymphocyte proliferation and production of interleukin-2. J Lab Clin Med 1986; 107: 471
    PubMedGoogle Scholar
  • 38 Lederman MM, Ratnoff OD, Scillian J, Jones PK, Schacter B. Impaired cell-mediated immunity in patients with classic hemophilia. N Engl J Med 1983; 308: 79
    CrossrefPubMedGoogle Scholar
  • 39 Vilmer E, Barre-Sinoussi F, Rouzioux C, Gazengel C, Vezinet-Brun F, Dauguet C, Fischer A, Manigne P, Chermann JC, Griscelli C, Montagnier L. Isolation of new lymphotrophic retrovirus from two siblings with hemophilia B, one with AIDS. Lancet 1984; 1: 753
    PubMedGoogle Scholar
  • 40 Prince AM, Horowitz B, Brotman B. Sterilization of hepatitis and HTLV-III viruses by exposure to tri (n-butyl) phosphate and sodium cholate. Lancet 1986; 1: 706
    PubMedGoogle Scholar
  • 41 Rouzioux C, Chalmaret S, Montagnier L, Camelli V, Rolland G, Mannucci PM. Absence of antibodies to AIDS virus in hemophiliacs treated with heat-treated factor VIII concentrate. Lancet 1984; 1: 753-757
    PubMedGoogle Scholar
  • 42 Study Group of the UK Hemophilia Center Directors on Surveillance of Virus Transmission by Concentrates. Effect of dry heating of Coagulation factor concentrates at 80° C for 72 hours on transmission of non A, nonB hepatitis. Lancet. 1988 2. 814
    PubMedGoogle Scholar
  • 43 McMillan CW, Shapiro SS, Whitehurst D, Hoyer LW, Rao AV, Lazerson J. and the Hemophilia Study Group The natural history of factor VIII : C inhibitors in patients with hemophilia A: A national cooperative study. II. Observations on the initial development of Factor VIII : C inhibitors. Blood 1988; 71: 344-348
    PubMedGoogle Scholar